LD-2 disclosure · 4th Quarter - Report
THE BIOSIMILARS FORUM
Client
- Description
- Non-profit Organization
- Location
- District of Columbia · United States of America
Registrant
- Description
- Government Affairs Firm
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
2 issuesHealth Issues
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2022 H.R. 2815, BIOSIM Act H.R. 2855, Star Rating for Biosimilars Act. H.R. 2869, Increasing Access to Biosimilars Act of 2021. S. 1427, Increasing Access to Biosimilars Act of 2021. Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
LobbyistsALEX DELPIZZO · STUART CHAPMAN
Covered position (ALEX DELPIZZO): Legislative Director/Legislative Asst, Rep. Ferguson; Staff Asst, House Transportation and Infrastructure Committee
Covered position (STUART CHAPMAN): Chief of Staff, Representative Carolyn McCarthy; Chief of Staff, Representative Zack Space; Press Secretary, Senator Jay Rockefeller; Press Secretary, Representative Barbara Lee
TargetedSENATE · HOUSE OF REPRESENTATIVES · Health & Human Services, Dept of (HHS) · Centers For Medicare and Medicaid Services (CMS)
Medicare/Medicaid
Drug pricing legislation. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2022. H.R. 2815, BIOSIM Act H.R. 2855, Star Rating for Biosimilars Act. H.R. 2869, Increasing Access to Biosimilars Act of 2021. S. 1427, Increasing Access to Biosimilars Act of 2021. Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.